Trial reportNutrients2021
Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis.
Trial report in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07287371 (Randomized Trial of Sucrosomial Iron Vs Intravenous Iron for Preoperative Anemia), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Trial of Sucrosomial Iron Vs Intravenous Iron for Preoperative Anemia (RSIVI)
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- NUTRITION MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN'S AND COLITIS (GEDIIB).Arquivos de gastroenterologia · 2026Pooled it
- Randomized trial of sucrosomial iron supplementation in patients with chemotherapy-related anemia treated with ESA.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Trial
- Efficacy of oral vs. intravenous iron for the treatment of iron deficiency anemia in different conditions: A systematic review and meta-analysis.Biomedical reports · 2026Article
- Advances in Iron Deficiency Anaemia Management: Exploring Novel Drug Delivery Systems and Future Perspectives.Current drug delivery · 2025Review
- Review
- Ginsenoside Rh2 suppresses ferroptosis in ulcerative colitis by targeting specific protein 1 by upregulating microRNA-125a-5p.European journal of medical research · 2024Article
- Review
- Comparative bioavailability study of supplemental oral SucrosomialFrontiers in nutrition · 2024Article
- SucrosomialPharmaceuticals (Basel, Switzerland) · 2023Review
- Sucrosomial® iron effectiveness in recovering from mild and moderate iron-deficiency anemia in the postpartum period.BMC pregnancy and childbirth · 2023Article
- A comparative absorption study of sucrosomialFrontiers in nutrition · 2023Article
- Short-term treatment of iron deficiency anemia after cardiac surgery.International journal of cardiology. Heart & vasculature · 2022Article
- Cost-effectiveness analysis of ferric carboxymaltoseTherapeutic advances in gastroenterology · 2022Article
- The Dietary Approach to the Treatment of the Rare Genetic Tubulopathies Gitelman's and Bartter's Syndromes.Nutrients · 2021Review
- Observational
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anemia is a frequent complication of ulcerative colitis, and is frequently caused by iron deficiency. Oral iron supplementation displays high rates of gastrointestinal adverse effects. However, the formulation of sucrosomial iron (SI) has shown higher tolerability. We performed a prospective study to compare the effectiveness and tolerability of oral SI and intravenous ferric carboxy-maltose (FCM) in patients with ulcerative colitis in remission and mild-to-moderate anemia. Patients were randomized 1:1 to receive 60 mg/day for 8 weeks and then 30 mg/day for 4 weeks of oral SI or intravenous 1000 mg of FCM at baseline. Hemoglobin and serum levels of iron and ferritin were assessed after 4, 8, and 12 weeks from baseline. Hemoglobin and serum iron increased in both groups after 4 weeks of therapy, and remained stable during follow up, without significant treatment or treatment-by-time interactions (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.